{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:43:07Z","timestamp":1766731387403,"version":"3.41.2"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The establishment of precision medicine is considered particularly important in heterogeneous autoimmune diseases (e.g., psoriatic arthritis, systemic lupus erythematosus), which reveal clinical and molecular heterogeneity. The selection of optimal treatment strategies for individual patients may be more important and complex in autoimmune diseases than in other diseases. Two factors are important in precision medicine: patient stratification and use of targeted. When both factors work, patients are likely to have good outcomes. However, research into precision medicine and its practice in systemic autoimmune diseases is lacking. In contrast, the usefulness of peripheral immune cell phenotyping in the evaluation of immunological characteristics and stratification into subgroups of individual patients with systemic autoimmune diseases such as immunoglobulin 4-related disease, systemic lupus erythematosus, and anti-neutrophil cytoplasmic antibody-related vasculitis was reported. Furthermore, the potential of precision medicine using biological disease-modifying antirheumatic drugs based on peripheral immune cell phenotyping was recently demonstrated for psoriatic arthritis in the clinical setting. Precision medicine has not yet been sufficiently investigated in real world clinical settings. However, a dawn of precision medicine has emerged. We should shed further light on precision medicine in PsA and other autoimmune diseases. Here, we first review the usefulness of peripheral immune cell phenotyping in systemic autoimmune diseases and the potential of precision medicine in PsA based on this method.<\/jats:p>","DOI":"10.3389\/fmed.2022.851892","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T10:22:38Z","timestamp":1647771758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Dawn of Precision Medicine in Psoriatic Arthritis"],"prefix":"10.3389","volume":"9","author":[{"given":"Ippei","family":"Miyagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1056\/NEJMra1615014","article-title":"Classification, ontology, and precision medicine","volume":"379","author":"Hendel","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/23808993.2020.1804867","article-title":"A wide perspective of targeted therapies for precision medicine in autoimmune diseases","volume":"6","author":"Miyagawa","year":"2020","journal-title":"Expert Rev Prec Med Drug Dev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B5","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"31","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"2","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000567","DOI":"10.1136\/rmdopen-2017-000567","article-title":"Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-na\u00efve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1","volume":"3","author":"Coates","year":"2017","journal-title":"RMD Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"79.700","DOI":"10.1136\/annrheumdis-2020-218456","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","author":"Gossec","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/art.40180","article-title":"Peripheral immunophenotyping identifies three subgroups based on t cell heterogeneity in lupus patients","volume":"69","author":"Kubo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/rheumatology\/kex455","article-title":"Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease","volume":"57","author":"Kubo","year":"2018","journal-title":"Rheumatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/rheumatology\/kex012","article-title":"Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis","volume":"57","author":"Nakayamada","year":"2018","journal-title":"Rheumatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-020-02215-x","article-title":"Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation","volume":"22","author":"Miyazaki","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39209","article-title":"Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease","volume":"67","author":"Akiyama","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab610.","article-title":"Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4\u2013related disease","author":"Zhang","year":"2021","journal-title":"Rheumatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jaci.2020.05.022","article-title":"CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease","volume":"147","author":"Perugino","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaci.2015.12.1330","article-title":"Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease","volume":"138","author":"Mattoo","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/rheumatology\/kex171","article-title":"Follicular helper T cells in the pathogenesis of IgG4-related disease","volume":"57","author":"Akiyama","year":"2018","journal-title":"Rheumatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"747076","DOI":"10.3389\/fimmu.2021.747076","article-title":"Peripheral B-cell immunophenotyping identifies heterogeneity in IgG4-related disease","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","article-title":"Follicular helper T cells in immunity and systemic autoimmunity","volume":"8","author":"Craft","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/art.39020","article-title":"Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity","volume":"67","author":"Choi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.immuni.2013.09.007","article-title":"Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure","volume":"39","author":"He","year":"2013","journal-title":"Immunity."},{"key":"B42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/cells8020140","article-title":"Immune profiling and precision medicine in systemic lupus erythematosus","volume":"8","author":"Nagafuchi","year":"2019","journal-title":"Cells"},{"key":"B43","doi-asserted-by":"publisher","first-page":"790122","DOI":"10.3389\/fimmu.2021.790122","article-title":"Molecular and cellular heterogeneity in rheumatoid arthritis: mechanisms and clinical implications","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e000415","DOI":"10.1136\/rmdopen-2016-000415","article-title":"Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial","volume":"3","author":"Mease","year":"2017","journal-title":"RMD Open"},{"key":"B45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS ONE"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"B48","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000484520","article-title":"Th17 inhibitors in active psoriatic arthritis: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"233","author":"Naik","year":"2017","journal-title":"Dermatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/jdv.15482","article-title":"Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation","volume":"33","author":"Dressler","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/23808993.2020.1724509","article-title":"Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine","volume":"5","author":"Chandran","year":"2020","journal-title":"Expert Rev Prec Med Drug Dev"},{"key":"B52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/1744666X.2019.1706484","article-title":"Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar2678","article-title":"Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis","volume":"11","author":"Badot","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13075-016-0919-z","article-title":"Higher expression of TNF\u03b1-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy","volume":"18","author":"De Groof","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.38202","article-title":"Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium","volume":"66","author":"Ducreux","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/art.30292","article-title":"Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium","volume":"63","author":"Gutierrez-Roelens","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","article-title":"Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab","volume":"71","author":"Hogan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"B59","unstructured":"Predicting the response to TNF inhibition or B cell depletion therapy from peripheral whole blood gene expression profiles in patients with rheumatoid arthritis\n            PorterD\n            GoodyearCS\n            NijjarJS\n            MessowM\n            SiebertS\n            MudaliarM\n          Arthritis Rheumatol2016"},{"key":"B60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12967-018-1387-9","article-title":"Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis","volume":"16","author":"Carini","year":"2018","journal-title":"J Transl Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.851892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T10:22:41Z","timestamp":1647771761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.851892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":60,"alternative-id":["10.3389\/fmed.2022.851892"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.851892","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"article-number":"851892"}}